Gastrointestinal Pharmaceuticals: Technologies and Markets

Report Code: PHM046B

Publish Date: Sep 2009

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2750

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

Overall sales in the gastrointestinal disorder treatment market amounted to $34.2 billionin 2007, and decreased slightly to $31.1 billion in 2009. By 2014, they are projected to reach $32.2 billion, for a 5-year compound annual growth rate (CAGR) of 0.7%.
The largest segment of the market, prescription gastrointestinal drugs, was valued at $27.4 billion in 2008; this is expected to decrease to $26,3 billion in 2009, and to reach $27 billion in 2014, for a 5-year CAGR of 0.5%.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The objectives of the study are to present a comprehensive look at disorders of the gastrointestinal system and their respective pharmaceutical treatment options. There are two large general categories of gastrointestinal drugs:

Prescription
Over-the-counter

Markets are further divided according to type of drug. The report is directed to decision-makers within the gastrointestinal market arena.

REASONS FOR DOING THE STUDY

This BCC study is presented to heighten the awareness of gastrointestinal disorders and identify pharmaceutical preparations and important advancements in the gastrointestinal markets. The study analyzes therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact on the future of both the prescription gastrointestinal drug market and the over-the-counter (OTC) gastrointestinal drug market. Manufacturers of gastrointestinal drug products have stepped up the pace of research and development as the engine driving growth in all markets, especially new treatments for Crohn’s disease and irritable bowel syndrome (IBS). Because of the evolving nature of the many areas of gastrointestinal disorders, executives involved in the specific areas within the gastrointestinal drug market must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities within the gastrointestinal marketplace.

INTENDED AUDIENCE

The information and analyses presented in this report are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and for consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for gastrointestinal drugs and, in particular, the market potential of technologies in development.

SCOPE OF REPORT

This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. The geographic scope of the report is global with a particular emphasis on the United States. Market data is global. The report provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and OTC arenas; and presents potential treatments in research and development, potential market size, and market participants. This report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future.

Within the market for gastrointestinal pharmaceuticals, categories are divided into two general segments:

Prescription gastrointestinal pharmaceuticals
Over-the-counter gastrointestinal pharmaceuticals

The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system including the following:

Gastrointestinal tract disorders
Gastrointestinal tract wall disorders
Gastrointestinal motility disorders
Gastrointestinal malabsorption disorders
Gastrointestinal cancers

Each sub segment is addressed in detail, describing disorders and the diseases, identifying current and potential products on the market, and competitors involved in the market.

METHODOLOGY AND INFORMATION SOURCES

The information and analysis presented in this BCC report are based on extensive firsthand interviews with primary executives, product managers, and clinical specialists in the gastrointestinal pharmaceutical arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of gastrointestinal disorders.

Key information from published literature was used to conduct interviews with more than 45 industry participants to validate and obtain expert opinions on current and future trends in the gastrointestinal pharmaceuticals industry. Interviews were the primary basis for development of market size. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.

All market data pertain to the global market with an emphasis on the U.S. market at the manufacturer’s level. Data are expressed in current U.S. dollars. The base year was 2009. Historical data are provided for 2007 and 2008 and forecast data are provided for 2014. Historical, base year and forecast data are provided for each market segment and sub segment. Market shares are provided for each market segment for the 2009 base year.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for the last 17 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceuticals industry. Ms. Crandall has a BS and MS in psychology and is a retired medical instructor.

BCC ONLINE SERVICES

Now you can locate the hard-to-find information you need on the Internet. By directing your browser to BCC’s new “home page,” you will be able to:

Examine our complete catalog of Market Research Reports and order directly from BCC
Subscribe to any of our more than 20 monthly technology/marketing newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information about any BCC product
Take advantage of special offers.

To reach this important new information resource, go to www.bccresearch.com

DISCLAIMER

This publication provides informative material of a professional nature. It does not constitute managerial, legal, or accounting advice, nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product. This information is intended to be as accurate as possible at the time of publication, but BCC Research assumes no responsibility for any losses or damages that might result because of reliance on this material.

Reproduction of any material in this report is strictly forbidden without express permission of the Publisher.

To receive a complete catalog of BCC Research studies, please complete the order form at the back of this report or visit our website at www.bccresearch.com.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Let us assist you! Our analysts are ready to tailor this report to your specific need. REACH OUT TO US TODAY

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com

[+] Show Chapter Details

Title/Chapter Name	Pages	Member Price
Full Report: Gastrointestinal Pharmaceuticals: Technologies and Markets	176	Free
Chapter- 1: INTRODUCTION	4	Free
STUDY GOALS AND OBJECTIVES REASONS FOR DOING THE STUDY INTENDED AUDIENCE SCOPE OF REPORT METHODOLOGY AND INFORMATION SOURCES ANALYST CREDENTIALS RELATED BCC REPORTS BCC ONLINE SERVICES DISCLAIMER
Chapter- 2: EXECUTIVE SUMMARY	2	Free
Table Summary : GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 Figure Summary : GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014
Chapter- 3: INDUSTRY OVERVIEW	43	Free
STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM LIVER, BILIARY TRACT AND PANCREAS GASTROINTESTINAL TRACT DISORDERS GASTROINTESTINAL TRACT WALL DISORDERS GASTROINTESTINAL TRACT MOTILITY DISORDERS GASTROINTESTINAL MALABSORPTION DISORDERS CANCERS OF THE GASTROINTESTINAL TRACT U.S. DEMOGRAPHICS PILL-SIZED VIDEO CAMERA SMARTPILL RADIO FREQUENCY IDENTIFICATION TECHNOLOGY IPHONE APPLICATION ENTERIC NERVOUS SYSTEM INSURANCE COVERAGE MONOCLONAL ANTIBODIES WYETH IN SUIT WITH STATES GENERIC INFLUENCE BRANDED VS OTC PROTON PUMP INHIBITORS MAIL ORDER TRENDS
Chapter- 4: PRESCRIPTION PRODUCT SEGMENTS BY TYPE	50	Free
ANTIDIARRHEALS ANTIEMETICS GASTROINTESTINAL CANCER TREATMENTS H2 INHIBITORS LAXATIVES PROTON PUMP INHIBITORS BOWEL ANTI-INFLAMMATORY OTHER GASTROINTESTINAL PRODUCTS TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS
Chapter- 5: OTC PRODUCT SEGMENTS BY TYPE	41	Free
ANTACIDS LOCALLY ACTING ANTIDIARRHEALS H2 INHIBITORS PROTON PUMP INHIBITORS LAXATIVES TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS RESEARCH AND DEVELOPMENT TOTAL MARKET ANALYSIS
Chapter- 6: INDUSTRY PARTICIPANTS BY PRODUCT TYPE	22	Free
C. CRAMER & CO. GMBH Table 54 : GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ REVENUES AND MARKET SHARE BY TYPE, 2009 Figure 33 : GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ MARKET SHARE BY TYPE, 2009
Chapter- 7: APPENDIX: CONTACT INFORMATION FOR GASTROINTESTINAL MARKET PARTICIPANTS	14	Free
3M CORP. ABBOTT LABORATORIES ABEILLE PHARMA, INC. ACAMBIS, PLC ACE BIOSCIENCES A/S AGI THERAPEUTICS, INC. ALCHEMIA, LTD. ALIZYME, PLC ALLERGAN, INC. ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. ALTANA PHARMA AG ALVINE PHARMACEUTICALS, INC. AMARIN CORP. AMGEN, INC. ANTIGENICS, INC. APOTHECON B.V. AP PHARMA, INC. ARCO PHARMACEUTICALS ASPHELIA PHARMACEUTICALS, INC. ARYX THERAPEUTICS, INC ASTELLAS PHARMA, INC. ASTRAZENECA, PLC AXCAN PHARMA, INC. BERTEK (MYLAN LABORATORIES INC.) BIOBALANCE, INC. BIOGEN IDEC, INC. BIOLINERX, LTD. BRAINTREE LABORATORIES, INC. BRISTOL-MYERS SQUIBB CO. CELLDEX THERAPEUTICS, INC. CENTOCOR ORTHO BIOTECH, INC. CEPHALON, INC. CERIMON PHARMA, INC. CHEMOCENTRYX, INC. CLAVIS PHARMA ASA COSMO PHARMACEUTICALS SPA CYTOKINE PHARMASCIENCES, INC. DEBIOPHARM S.A. DOR BIOPHARMA, INC. EISAI CO., LTD. ELAN CORPORATION, PLC EMD SERONO, INC. ENZO EURAND PHARMACEUTICALS, INC. EVOKE PHARMA FRESENIUS KABI AG GENENTECH, INC. GENZYME GENERAL GLAXOSMITHKLINE, PLC GLAXOSMITHKLINE CONSUMER HEALTHCARE GLENMARK PHARMACEUTICALS, LTD. H3 PHARMA, INC. HELSINN HEALTHCARE HOFFMAN-LAROCHE, LTD. (ROCHE) HYPERION THERAPEUTICS, INC. IMMUCELL CORP. ISIS PHARMACEUTICALS. INC. JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON) JOHNSON & JOHNSON LORUS THERAPEUTICS, INC. MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS MEDISCA, INC. MERCK & CO., INC. MONARCH LABS NABI BIOPHARMACEUTICALS NOVARTIS CORP. NPS PHARMACEUTICALS, INC. OTSUKA AMERICA PHARMACEUTICAL, INC. PFIZER, INC. THE PROCTER & GAMBLE CO. PRODIGENE, INC. PROGENICS PHARMACEUTICALS, INC. RAVEN BIOTECHNOLOGIES, INC. RELIANT PHARMACEUTICALS, INC. ROXANE LABORATORIES, INC. SALIX PHARMACEUTICALS, LTD. SANOFI-AVENTIS SANTARUS, INC. SCHERING AG SCHWARZ PHARMA AG SERONO S.A. SHIRE PHARMACEUTICALS GROUP, PLC SOLVAY S.A. SUCAMPO PHARMACEUTICALS, INC. SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC) TAKEDA PHARMACEUTICAL NORTH AMERICA TARGACEPT, INC. THERAVANCE, INC. UCB PHARMA, INC. UNIMED PHARMACEUTICALS, INC. PHARMOS PHARMACEUTICALS, INC. WATSON PHARMACEUTICALS, INC. WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.)

Published - Sep-2005| Analyst - Mary Anne Crandall| Code - PHM046A

Report Highlights

The total U.S. market for gastrointestinal disorder treatments was estimated at $16.1 billion for 2004. Rising at an AAGR (average annual growth rate) of 7.3%, the market is expected to reach $22.8 billion in 2009.
The prescription market accounted for the largest percentage of sales with approximately 85%, or $13.7 billion in sales in for 2004. This segment is also rising the fastest, with an AAGR of 7.7%.
The OTC market accounts for the remaining 15%, or $2.4 billion. Rising at AAGR of 14%, it will represent only 13% of the market in 2009.
At approximately 80%, the largest area of market participation for leading competitors is within the prescription drug segment.

Related Reports

Recent Reports

Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets

Published - Apr 2024 | Publisher - BCC Publishing | Code - PHM046D

The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.

Global Markets and Technologies for Advanced Drug Delivery Systems

Published - Mar 2024 | Publisher - BCC Publishing | Code - PHM006N

The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM113C

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

Global Markets for Vaccine Technologies

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM014K

The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.

Chagas Disease: American trypanosomiasis Market

Published - Feb 2024 | Publisher - BCC Publishing | Code - PHM282A

The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.

Top Trending Reports

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2022 | Publisher - BCC Publishing | Code - BIO208B

The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.

Flame Retardant Chemicals: Technologies and Global Markets

Published - Nov 2022 | Publisher - BCC Publishing | Code - CHM014Q

The global consumption of flame retardant chemicals is estimated to grow from 6.0 billion pounds in 2022 to 7.5 billion pounds in 2027, at a compound annual growth rate (CAGR) of 4.4% for the period of 2022-2027.

Biorefinery Products: Global Markets

Published - Nov 2022 | Publisher - BCC Publishing | Code - EGY117D

The global market for biorefinery products is estimated to increase from $624.7 billion in 2022 to $920.0 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

Electric Vehicle Charging: Infrastructure and Global Markets

Published - Nov 2022 | Publisher - BCC Publishing | Code - FCB045B

The global market for wired electric vehicle charging infrastructure is estimated to grow from $24.1 billion in 2022 to $81.1 billion in 2027, at a compound annual growth rate (CAGR) of 27.4% for the period of 2022-2027.

Digital Pathology: Technologies and Global Markets

Published - Dec 2022 | Publisher - BCC Publishing | Code - HLC161D

The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.

FAQ

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More

Gastrointestinal Pharmaceuticals: Technologies and Markets

Report Highlights

Table of Contents

Report Highlights

Related Reports

Recent Reports

Top Trending Reports

Become A Member

Custom Consulting

Scorecard

Innovation Spotlight